Compare RGNX & NMFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGNX | NMFC |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.1M | 796.4M |
| IPO Year | 2015 | N/A |
| Metric | RGNX | NMFC |
|---|---|---|
| Price | $9.30 | $8.23 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | ★ $28.75 | $8.63 |
| AVG Volume (30 Days) | 570.9K | ★ 1.1M |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 15.74% |
| EPS Growth | ★ 18.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,393,000.00 | N/A |
| Revenue This Year | $50.15 | N/A |
| Revenue Next Year | $23.42 | N/A |
| P/E Ratio | ★ N/A | $12.51 |
| Revenue Growth | ★ 126.48 | N/A |
| 52 Week Low | $5.85 | $7.47 |
| 52 Week High | $16.19 | $11.04 |
| Indicator | RGNX | NMFC |
|---|---|---|
| Relative Strength Index (RSI) | 57.11 | 61.26 |
| Support Level | $7.76 | $7.50 |
| Resistance Level | $10.08 | $8.28 |
| Average True Range (ATR) | 0.51 | 0.21 |
| MACD | 0.16 | 0.07 |
| Stochastic Oscillator | 95.65 | 100.00 |
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.